CJC-1295 is a GHRH analog that raises the growth-hormone "signal," while Ipamorelin is a selective ghrelin-receptor (GHS-R) agonist that amplifies the GH pulse. Researchers pair them because they act on two different but complementary pathways at once. These are research compounds only, not for human use, and most of the supporting evidence is preclinical or early-stage.
CJC-1295 and Ipamorelin are two research peptides studied together because they push on the growth-hormone system from two different directions at once. CJC-1295 is a growth-hormone-releasing-hormone (GHRH) analog that raises the underlying GH "signal." Ipamorelin is a selective growth-hormone secretagogue that acts on the ghrelin receptor to amplify the natural GH pulse. Neither is approved for human use; both are handled strictly as research chemicals.
What CJC-1295 is
CJC-1295 is a synthetic analog of GHRH, the hormone the body naturally uses to tell the pituitary to release growth hormone. In research terms, it mimics that upstream signal. A raw GHRH peptide breaks down in minutes, so CJC-1295 was engineered to resist that rapid degradation, which is what gives it a longer working half-life than native GHRH.
There are two versions people mean when they say "CJC-1295," and confusing them is the single most common mistake:
- CJC-1295 no-DAC (also called Mod GRF 1-29 or CJC-1295 without DAC): a short-acting GHRH analog. It clears relatively quickly, so in study models it tends to produce a sharper, more pulse-like GH response.
- CJC-1295 with DAC: the same peptide plus a Drug Affinity Complex (DAC). The DAC lets the molecule bind to albumin in the blood, which dramatically extends its half-life from minutes to a much longer window measured in days in research characterizations.
DAC is the whole distinction. It doesn't change what the peptide targets; it changes how long the peptide sticks around. You can read the full breakdown on the CJC-1295 compound page.
What Ipamorelin is
Ipamorelin is a growth-hormone secretagogue that works through a completely different receptor: the ghrelin receptor (GHS-R). Ghrelin is the "hunger hormone," and its receptor is one of the body's other levers for triggering GH release. Ipamorelin is a synthetic pentapeptide that flips that lever without being ghrelin itself.
The reason Ipamorelin gets singled out among growth-hormone-releasing peptides (GHRPs) is selectivity. Older GHRPs like GHRP-6 and GHRP-2 are known in the literature to also nudge other signaling: appetite and hunger, cortisol, and prolactin. Ipamorelin is characterized in research as much cleaner. In studies it triggers GH release with far less associated cortisol, prolactin, or hunger signaling. That relatively narrow action is why it's often the GHS-R agonist of choice in newer research designs.
More detail lives on the Ipamorelin compound page, and the Ipamorelin vs GHRP-6 comparison walks through the selectivity difference directly.
Why they're researched together
GH release isn't controlled by one switch. It runs on at least two: the GHRH pathway (the "go" signal) and the ghrelin/GHS-R pathway (the "amplify" signal). There's also a brake, somatostatin, that dampens release.
- CJC-1295 works the GHRH pathway. It raises the releasing signal.
- Ipamorelin works the GHS-R pathway. It strengthens the pulse and, in models, helps blunt the somatostatin brake.
Because they hit two different receptors, researchers study them as a stack rather than picking one. The idea is that a GHRH analog plus a GHS-R agonist can produce a more complete, more natural-shaped GH pulse in study models than either compound alone. One raises the signal, the other amplifies the release. That complementary mechanism is the entire reason this specific combination became the default growth-hormone-secretagogue research pairing.
Important caveat, stated plainly: most of the evidence here is preclinical or early-stage. A lot of it is animal-model and cell-study work plus limited human data. Treat mechanistic descriptions as "this is how it's understood to work," not as proven clinical outcomes.
CJC-1295 no-DAC vs CJC-1295 DAC vs Ipamorelin
| Compound | Class / mechanism | Half-life character | Research note |
|---|---|---|---|
| CJC-1295 no-DAC (Mod GRF 1-29) | GHRH analog; raises the GH-releasing signal | Short; clears relatively fast | Studied for a sharper, pulse-like GH response in models |
| CJC-1295 with DAC | GHRH analog + Drug Affinity Complex (albumin-binding) | Much longer; extended over days in research characterizations | DAC extends duration only; the target is the same GHRH pathway |
| Ipamorelin | Selective GHS-R (ghrelin-receptor) agonist; amplifies the GH pulse | Short-acting | More selective than older GHRPs; less associated cortisol/prolactin/hunger signaling in studies |
The table makes the key point: CJC-1295 and Ipamorelin are not two versions of the same thing. They target different receptors. And within CJC-1295 itself, DAC vs no-DAC is purely a duration question.
Why blends are common
Because the two compounds target different pathways and are studied in combination, they're frequently supplied as a single lyophilized blend rather than two separate vials. A blend keeps the research ratio fixed and simplifies handling. The most common pairing you'll see is a no-DAC CJC-1295 (Mod GRF 1-29) with Ipamorelin, sold at matched milligram amounts. You can see how the combined product is catalogued on the CJC-1295 + Ipamorelin blend page.
General lab handling and storage
This section is about laboratory handling of the material, not about using it in a person.
Peptide blends like this ship lyophilized: freeze-dried into a dry powder or pellet, which is the stable form for shipping and storage. For research work, the powder is reconstituted with an appropriate solvent (commonly bacteriostatic water) to bring it into solution. Reconstitution is a lab step, not a dosing instruction. The mechanics of doing it correctly, including solvent choice, gentle mixing rather than shaking, and avoiding foaming, are covered in the complete peptide reconstitution guide.
A few general storage principles for lyophilized and reconstituted peptides:
- Keep the dry powder cold. Lyophilized peptides are typically stored refrigerated, and frozen for long-term storage.
- Once reconstituted, it's less stable. Solutions are kept refrigerated and used within a shorter window than the dry powder.
- Protect from light and heat. Both degrade peptides.
- Avoid freeze-thaw cycling of reconstituted solution, which can degrade the peptide.
The full walkthrough is in the peptide storage guide.
Sourcing and verifying quality
Quality control matters more than brand for research peptides, because purity and correct identity are the whole point. Whatever the source, the thing to check is a Certificate of Analysis (COA) tied to the specific lot: third-party testing that confirms identity and purity for that batch, not a generic marketing claim.
One reputable, COA-per-lot option is BHG Labs, which stocks a CJC-1295 + Ipamorelin 5mg+5mg blend. *Independent vendor; BodyHackGuide may earn a commission.* Reader discount code REDDIT takes 10% off.
BHG Labs is one option, not the only one. The more useful habit is knowing how to vet any vendor yourself. Learn to read a lab report with how to read a peptide COA, compare sources on the vendor scorecard, or read the full BHG Labs vendor profile before deciding.
Frequently asked
Weekly drops, weekly research
New guides, price-drop alerts, and reader-submitted protocols. One email a week. Unsubscribe anytime.
No spam. Unsubscribe anytime.
Discussion
Sign in to join the discussion
No comments yet โ be the first to share your thoughts!